The efficacy and safety of Chinese herbal medicine Jinlida as add-on medication in type 2 diabetes patients ineffectively managed by metformin monotherapy: A double-blind, randomized, placebo-controlled, multicenter trial

PLoS ONE

Volumn 10, Issue 6, 2015, Pages

  Lian, Fengmei ^a   Tian, Jiaxing ^a   Chen, Xinyan ^a   Li, Zhibin ^b   Piao, Chunli ^c   Guo, Junjie ^d   Ma, Licheng ^e   Zhao, Lijuan ^f   Xia, Chengdong ^g   Wang, Chong Zhi ^h   Yuan, Chun Su ^h   Tong, Xiaolin ^a  

^a INSTITUTE OF CHINESE MATERIA MEDICA   (China)

^b Shijiazhuang Hospital of Traditional Chinese Medicine   (China)

^c CHANGCHUN UNIVERSITY OF CHINESE MEDICINE   (China)

^d Shanxi Province Hospital of Traditional Chinese Medicine   (China)

^e BETHUNE INTERNATIONAL PEACE HOSPITAL   (China)

^f SHANXI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^g XIYUAN HOSPITAL   (China)

^h UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (3,4 DIHYDROXYPHENYL)LACTIC ACID; EPIMEDIN B; EPIMEDIN C; GINSENOSIDE RB 1; GINSENOSIDE RB 2; GINSENOSIDE RC; GLUCOSE; HEMOGLOBIN A1C; HERBACEOUS AGENT; ICARIIN; JINLIDA; METFORMIN; PLACEBO; PLANT MEDICINAL PRODUCT; PUERARIN; SALVIANOLIC ACID B; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ADD ON THERAPY; ADULT; ANTIDIABETIC ACTIVITY; ARTICLE; BODY MASS; BODY WEIGHT; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG CAPSULE; DRUG DETERMINATION; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; ECG ABNORMALITY; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HERBAL MEDICINE; HUMAN; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MONOTHERAPY; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL FUNCTION; POWDER; RANDOMIZED CONTROLLED TRIAL; UNSPECIFIED SIDE EFFECT; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; METABOLISM; PHYSIOLOGY; PROCEDURES;

BODY WEIGHT; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; DRUGS, CHINESE HERBAL; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; MALE; METFORMIN; MIDDLE AGED;

EID: 84939169588     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0130550     Document Type: Article

References (38)

1. World Health Organization. Country and regional data on diabetes. Available: http://www.who.int/diabetes/facts/world-figures/en/. Accessed 28 November 2014.
2. Yang W, Lu J, Weng J, Jia W, Ji L, Xiao J, et al. China National Diabetes and Metabolic Disorders Study Group. (2010) Prevalence of Diabetes among Men and Women in China. N Engl J Med 362: 1090-1101. doi: 10.1056/NEJMoa0908292 PMID: 20335585
3. UK Prospective Diabetes Study Group. (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 13: 837-853.
4. Skyler JS, Bergenstal R, Bonow RO, Buse J, Deedwania P, Gale EA, et al.; American Diabetes Association; American College of Cardiology Foundation; American Heart Association. (2009) Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Diabetes Care 13: 187-192.
5. American Diabetes Association. (2014) Standards of medical care in diabetes-2014. Diabetes Care 37: S14-S80. doi: 10.2337/dc14-S014 PMID: 24357209
6. Chinese Diabetes Society. (2013) China guideline for type 2 diabetes. Beijing, BJ, Chinese Medical Multimedia Press.
7. Ji LN, Lu JM, Guo XH, Yang WY, Weng JP, Jia WP, et al. (2013) Glycemic control among patients in China with type 2 diabetes mellitus receiving oral drugs or injectables. BMC Public Health 13: 602. doi: 10.1186/1471-2458-13-602 PMID: 23800082
8. Fonseca V, Rosenstock J, Patwardhan R, Salzman A. (2000) Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. JAMA. 283: 1695-1702. PMID: 10755495
9. TODAY Study Group, Zeitler P, Hirst K, Pyle L, Linder B, Copeland K, Arslanian S, et al. (2012) A Clinical trial to maintain glycemic control in youth with type 2 diabetes. N Engl J Med 366: 2247-2256. doi: 10.1056/NEJMoa1109333 PMID: 22540912
10. Fouqueray P, Pirags V, Inzucchi SE, Bailey CJ, Schernthaner G, Diamant M, et al. (2013) The efficacy and safety of imeglimin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy. Diabetes Care 36: 565-568. doi: 10.2337/dc12-0453 PMID: 23160726
11. Tong XL, Dong L, Chen L, Zhen Z. (2012) Treatment of diabetes using traditional Chinese medicine: past, present and future. Am J Chin Med 40: 877-886. doi: 10.1142/S0192415X12500656 PMID: 22928822
12. Tong XL, Wu ST, Lian FM, Zhao M, Zhou SP, Chen XY, et al. (2013) The safety and effectiveness of TM81, a Chinese herbal medicine, in the treatment of type 2 diabetes: a randomized double-blind placebo-controlled trial. Diabetes Obes Metab. 15: 448-454. doi: 10.1111/dom.12051 PMID: 23231379
13. Ji L, Tong X, Wang H, Tian H, Zhou H, Zhang L, et al.; Evidence-Based Medical Research of Xiaoke Pill Study Group. Evidence-Based Medical Research of Xiaoke Pill Study Group. (2013) Efficacy and safety of Traditional Chinese medicine for diabetes: a double-blind, randomised, controlled trial. PLoS One 8: e56703. doi: 10.1371/journal.pone.0056703 PMID: 23460810
14. Lian F, Li G, Chen X, Wang X, Piao C, Wang J, et al. (2014) Chinese herbal medicine Tianqi reduces progression from impaired glucose tolerance to diabetes: a double-blind, randomized, placebo-controlled, multicenter trial. J Clin Endocrinol Metab 99: 648-655. doi: 10.1210/jc.2013-3276 PMID: 24432995
15. Pang J, Gao HL, Wang HT, Wei C, Wu YL. (2014) A study on the effect of Jinlida on blood sugar regulating hormone and islet cell function in diabetic rats. Chin J Basic Med Tradit Chine Med 20: 605-607.
16. Zheng Y, Yan FQ, Wang HY. (2013) The impact of Jinlida granule on the islet function and TNF-α level in patients with type 2 diabetes, and evaluation on its efficacy and safety. Chin J Basic Med Tradit Chine Med 19: 654-656.
17. Guo M, Liu Y. (2013) Effects of Jinlida granule combined with metformin on treatment of patients with initial type 2 diabetes. J Clin Med Pract 17: 35-37.
18. Li JB, Wang DK, Lu FE, Liu C. (2013) Evaluation on the efficacy and safety of Jinlida granule in the treatment of type 2 diabetes. Eval Anal Drug-Use Hospit Chin 13: 591-594.
19. World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications: report of a WHO consultation. Part I: Diagnosis and classification of diabetes mellitus. Geneva, 1999.
20. Lu JM, Ji LN, Guo XH. The status quo of type 2 diabetes patients with blood sugar level properly controlled by taking oral hypoglycemic agents in urban areas of China. (2012) Chin J Diabetes 4: 402-406. doi: 10.1111/j.2040-1124.2012.00209.x PMID: 24843597
21. Kirpichnikov D, McFarlane SI, Sowers JR. Metformin: an update. (2002) Ann Intern Med 137: 25-33. PMID: 12093242
22. Bolen S, Feldman L, Vassy J, Wilson L, Yeh HC, Marinopoulos S, et al. (2007) Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med 147: 386-399. PMID: 17638715
23. Salpeter S, Greyber E, Pasternak G, Salpeter E. (2006) Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev 1: CD002967. PMID: 16437448
24. So WY, Raboca J, Sobrepena L, Yoon KH, Deerochanawong C, Ho LT, et al.; JADE Program Research Team. (2011) Comprehensive risk assessments of diabetic patients from seven Asian countries: the Joint Asia Diabetes Evaluation (JADE) program. J Diabetes 3: 109-118. doi: 10.1111/j.1753-0407.2011.00115.x PMID: 21599865
25. Rodbard HW, Jellinger PS, Davidson JA, Einhorn D, Garber AJ, Grunberger G, et al. (2009) Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract. 15: 540-559. PMID: 19858063
26. DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. (1995) The Multicenter Metformin Study Group. N Engl J Med 333: 541-549. PMID: 7623902
27. Inzucchi SE, Maggs DG, Spollett GR, Page SL, Rife FS, Walton V, et al. (1998) Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med 338: 867-872. PMID: 9516221
28. Fonseca V, Rosenstock J, Patwardhan R, Salzman A. (2000) Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. JAMA 283: 1695-1702. PMID: 10755495
29. DeFronzo RA, Hissa MN, Garber AJ, Luiz Gross J, Yuyan Duan R, Ravichandran S, et al.; Saxagliptin 014 Study Group. (2009) The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. Diabetes Care 32: 1649-1655. doi: 10.2337/dc08-1984 PMID: 19478198
30. Nauck MA, Del Prato S, Meier JJ, Durán-García S, Rohwedder K, Elze M, et al. (2011) Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care 34: 2015-2022. doi: 10.2337/dc11-0606 PMID: 21816980
31. Fouqueray P, Pirags V, Inzucchi SE, Bailey CJ, Schernthaner G, Diamant M, et al. (2013) The efficacy and safety of imeglimin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy. Diabetes Care 36: 565-568. doi: 10.2337/dc12-0453 PMID: 23160726
32. Zhang X, Yang L, Sun L, Ren J, Han S, Gu L, et al. (2013) Jinlida granule in treatment of patients with type 2 diabetes: a randomized and double-blind clinical study. Chin J Diffic Compl Case 12: 351-353.
33. Gao Y, Zhou H, Zhao H, Feng X, Feng J, Li Y, et al. (2013) Clinical research of traditional Chinese medical intervention on impaired glucose tolerance. Am J Chin Med 41: 21-32. doi: 10.1142/S0192415X1350002X PMID: 23336504
34. Prasain JK, Peng N, Rajbhandari R, Wyss JM. (2012) The Chinese Pueraria root extract (Pueraria lobata) ameliorates impaired glucose and lipid metabolism in obese mice. Phytomedicine 20: 17-23. doi: 10.1016/j.phymed.2012.09.017 PMID: 23123226
35. Wu K, Liang T, Duan X, Xu L, Zhang K, Li R. (2013) Anti-diabetic effects of puerarin, isolated from Pueraria lobata (Willd.), on streptozotocin-diabetogenic mice through promoting insulin expression and ameliorating metabolic function. Food Chem Toxicol 60: 341-347. doi: 10.1016/j.fct.2013.07.077 PMID: 23927877
36. Li Z, Shangguan Z, Liu Y, Wang J, Li X, Yang S, et al. (2014) Puerarin protects pancreatic β-cell survival via PI3K/Akt signaling pathway. J Mol Endocrinol 53: 71-79. doi: 10.1530/JME-13-0302 PMID: 24827001
37. Attele AS, Zhou YP, Xie JT, Wu JA, Zhang L, Dey L, et al. (2002) Antidiabetic effects of Panax ginseng berry extract and the identification of an effective component. Diabetes 51: 1851-1858. PMID: 12031973
38. Xie JT, Mehendale S, Yuan CS. Ginseng and diabetes. (2005) Am J Chin Med. 33: 397-404. PMID: 16047557